PURPOSE: The aim of the study was to determine the perimetric rate of glaucoma progression in the ongoing Glaucoma Intensive Treatment Study (GITS) after 3 years of follow-up.DESIGN: This is a randomized, two-centre, prospective open-labelled treatment trial for open-angle glaucoma (OAG).PARTICIPANTS: The participants of this study were treatment-naive patients with newly diagnosed OAG, aged 46-78 years, with early to moderate glaucomatous visual field loss scheduled to be followed for 5 years within the study.METHODS: Patients were randomized to initial treatment with either topical monotherapy or with an intensive approach using drugs from three different classes, plus 360° laser trabeculoplasty. Changes in treatment were allowed. Standar...
Purpose: To study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differenc...
Objective: To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including ...
Background: Presentation with advanced glaucoma is the major risk factor for lifetime blindness. Eff...
Purpose: The aim of the study was to determine the perimetric rate of glaucoma progression in the on...
Purpose: The aim of the study was to determine the perimetric rate of glaucoma progression in the on...
Funding text Financial support was provided through regional agreements between Lund University and ...
Funding text Financial support was provided through regional agreements between Lund University and ...
PURPOSE: To study newly diagnosed glaucoma patients given mono- or multi-therapy regarding differenc...
PURPOSE: To study newly diagnosed glaucoma patients given mono- or multi-therapy regarding differenc...
Purpose: To determine progression factors at the end of the Early Manifest Glaucoma Trial (EMGT) bas...
Background: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affec...
Purpose: To study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differenc...
Purpose: To study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differenc...
Purpose: To evaluate the long-term effect of laser trabeculoplasty (LTP) in patients randomized to m...
BACKGROUND: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affec...
Purpose: To study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differenc...
Objective: To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including ...
Background: Presentation with advanced glaucoma is the major risk factor for lifetime blindness. Eff...
Purpose: The aim of the study was to determine the perimetric rate of glaucoma progression in the on...
Purpose: The aim of the study was to determine the perimetric rate of glaucoma progression in the on...
Funding text Financial support was provided through regional agreements between Lund University and ...
Funding text Financial support was provided through regional agreements between Lund University and ...
PURPOSE: To study newly diagnosed glaucoma patients given mono- or multi-therapy regarding differenc...
PURPOSE: To study newly diagnosed glaucoma patients given mono- or multi-therapy regarding differenc...
Purpose: To determine progression factors at the end of the Early Manifest Glaucoma Trial (EMGT) bas...
Background: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affec...
Purpose: To study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differenc...
Purpose: To study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differenc...
Purpose: To evaluate the long-term effect of laser trabeculoplasty (LTP) in patients randomized to m...
BACKGROUND: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affec...
Purpose: To study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differenc...
Objective: To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including ...
Background: Presentation with advanced glaucoma is the major risk factor for lifetime blindness. Eff...